Banavali S D, Patil N R, Nirabhawane V S, Bhosale B B, Desai S B
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
Indian J Cancer. 2013 Apr-Jun;50(2):149-53. doi: 10.4103/0019-509X.117029.
Cholangiocarcinoma (CCa) is relatively resistant to chemotherapy as well as radiation therapy, and complete resection is the main curative therapy for these patients. The prognosis for patients with unresectable intrahepatic CCa (iCCa) is extremely poor. A 55-year-old woman presented at our hospital with abdominal pain. After evaluation, she was diagnosed to have multifocal iCCa. She did not opt for standard chemotherapy and therefore received oral metronomic therapy with a combination of celecoxib, etoposide, and cyclophosphamide for a total of 30 months. Presently, she is 57 months post diagnosis and 27 months post cessation of all treatment and continues to be in complete radiological remission. In the present report, we review the literature and discuss whether metronomic scheduling of biologic agents and anticancer drugs will be able to overcome chemoresistance and improve the outcome in cholangiocarcinoma. References for the review were identified through searches of Pubmed for the last 10 years as well as searches of the files of the authors themselves. The final list was generated on the basis of originality and relevance to this review.
胆管癌（CCa）对化疗和放疗相对耐药，完整切除是这些患者的主要治愈性疗法。无法切除的肝内胆管癌（iCCa）患者的预后极差。一名55岁女性因腹痛就诊于我院。经评估，她被诊断为多灶性iCCa。她未选择标准化疗，因此接受了塞来昔布、依托泊苷和环磷酰胺联合的口服节拍器疗法，共治疗30个月。目前，她已确诊57个月，停止所有治疗27个月，仍处于完全影像学缓解状态。在本报告中，我们回顾了文献，并讨论生物制剂和抗癌药物的节拍给药方案是否能够克服化疗耐药性并改善胆管癌的治疗结果。通过检索过去10年的PubMed以及作者自身的文献档案来确定该综述的参考文献。最终列表是根据原创性和与本综述的相关性生成的。
